Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Summary

The purpose of this study is to determine whether MIS416 administered once weekly over 12 months is safe, tolerable, and improves a range of signs and symptoms associated with secondary progressive multiple sclerosis.

Timeline

Start

2014-10

Primary completion

2017-05

Completion

2017-06

Drugs

Indications